Overview

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2017-11-14
Target enrollment:
Participant gender:
Summary
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
Phase:
Phase 2
Details
Lead Sponsor:
EMD Serono Research & Development Institute, Inc.
Collaborators:
Merck KGaA
Merck KGaA, Darmstadt, Germany